{"analyses":[{"ciLowerLimit":"0.26","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.48","estimateComment":"The HR was adjusted for World Health Organization (WHO) performance status scale (0 versus 1 at Baseline) and number of prior lines of systemic treatment for advanced disease (0/1 versus 2+).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Stratified two-sided log rank p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.35","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"8.1","value":"7.0"},{"groupId":"OG001","lowerLimit":"17.9","upperLimit":"21.3","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"description":"PFS was defined as the time interval between the date of randomization and the earliest date of either disease progression or death due to any cause. The diagnosis of progression was based on tumor measurements, according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria, by independent radiologic assessment. The Kaplan-Meier method was used for PFS estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population: all randomized participants analyzed in the treatment arm they were allocated by randomization.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until the date of the first documented radiological progression or date of death from any cause, whichever came first (assessed for an average of 10 months)","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"weeks"}